Earnings summaries and quarterly performance for Esperion Therapeutics.
Executive leadership at Esperion Therapeutics.
Board of directors at Esperion Therapeutics.
Research analysts who have asked questions during Esperion Therapeutics earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
3 questions for ESPR
Also covers: ARMP, BCDA, BLRX +15 more
Serge Belanger
Needham & Company
3 questions for ESPR
Also covers: AMPH, ARQT, BCRX +12 more
Jason Zemansky
Bank of America
2 questions for ESPR
Also covers: ABOS, BBIO, CYTK +5 more
Jessica Fye
JPMorgan Chase & Co.
2 questions for ESPR
Also covers: ALKS, ALNY, AMRN +23 more
Kristen Kluska
Cantor Fitzgerald
2 questions for ESPR
Also covers: ABEO, ADMA, AQST +24 more
Tom Shrader
BTIG
2 questions for ESPR
Also covers: ABOS, ALDX, ALEC +4 more
Georgia Bank
Jefferies
1 question for ESPR
Paul Choi
Goldman Sachs
1 question for ESPR
Also covers: AMRN, ARVN, ASND +12 more
Recent press releases and 8-K filings for ESPR.
Esperion Therapeutics Highlights Bempedoic Acid's Market Expansion, Strong Performance, and Pipeline Progress
ESPR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Bempedoic acid (Nexletol/Nexlizet) has achieved strong access, volume, and sales growth, with a broad label expansion in April 2024 increasing its Total Addressable Market (TAM) from 10 million to 70 million patients.
- The drug received a Class 1A recommendation in European guidelines, positioning it as a foundational lipid-lowering therapy, with similar U.S. guidelines anticipated in early 2025.
- Esperion has secured patent exclusivity for bempedoic acid until at least 2031, with confidence in extending it "well into the 2030s".
- International markets are performing strongly, with Europe having over 600,000 patients on the drug and Japan's recent approval triggering a $90 million milestone payment.
- The company is developing a triple combo pill for market entry by end of 2027 and advancing a next-generation ACLY inhibitor (ESP-2001) into human studies by late 2026.
2 days ago
Esperion Therapeutics Discusses Bempedoic Acid Market Expansion, Guidelines, and Exclusivity
ESPR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion Therapeutics highlighted the broad label expansion for bempedoic acid in April 2024, which increased its Total Addressable Market (TAM) from 10 million to 70 million patients, enabling promotion for use with or without statins.
- Bempedoic acid received a Class I-A recommendation in the European Society of Cardiology (ESC) guidelines for statin-intolerant patients, positioning it as a foundational therapy, with similar positive influence anticipated for upcoming U.S. guidelines.
- The company maintains strong payer access in the U.S., with 90% commercial coverage and 85% Medicare coverage. Internationally, Europe has over 600,000 patients with high double-digit growth, and a $90 million milestone was received for the recent approval in Japan.
- Esperion is confident in bempedoic acid's exclusivity until at least 2031, with expectations to extend "well into the 2030s". A triple combo pill is targeted for market by the end of 2027, and a next-generation ACLY inhibitor (ESP-2001) is expected to be IND-enabled by late 2026.
2 days ago
Esperion Therapeutics Highlights Bempedoic Acid Market Expansion and Future Outlook
ESPR
Product Launch
Legal Proceedings
New Projects/Investments
- Esperion's bempedoic acid saw its Total Addressable Market (TAM) expand from 10 million to 70 million patients in April 2024 following a broad label expansion.
- The drug received a Class 1A recommendation in the European Society of Cardiology (ESC) guidelines, positioning it as foundational therapy, with similar U.S. guidelines anticipated in early 2026.
- U.S. payer access is strong, with 90% commercial coverage and 85% Medicare coverage, and the company expects to be selling exclusively "well into the 2030s" due to patent settlements.
- International markets are performing well, with over 600,000 patients on the drug in Europe and a $90 million milestone received for the Japan launch.
- Esperion is developing a triple combination pill with bempedoic acid and ezetimibe, aiming for market entry by the end of 2027, and advancing a next-generation ACLY inhibitor (ESP-2001) into human studies by late 2026.
2 days ago
Esperion Therapeutics Provides Updates on Market Expansion, Profitability, and Pipeline
ESPR
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Esperion Therapeutics' bempedoic acid received an updated cardiovascular outcomes trial label in April 2024, expanding its addressable market from 10 million to 70 million patients, and has since shown double-digit growth quarter over quarter.
- The company anticipates achieving sustainable profitability in Q1 2026 and expects to end 2025 with less debt.
- Bempedoic acid received a Class 1A recommendation in European guidelines in September, with US guidelines expected in early 2026 (January/February). Additionally, Esperion expects up to $120 million in milestones from Japan's approval and tentative pricing in September.
- Esperion plans an incremental expansion of its current 155 sales representatives to capitalize on upcoming US guidelines and patent wins, and reported a pro forma cash position of approximately $170 million after Q3.
Nov 18, 2025, 8:00 AM
Esperion Therapeutics Discusses Market Expansion, Upcoming Guidelines, and Path to Profitability
ESPR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion Therapeutics received an updated label for its cardiovascular outcomes trial in April 2024, expanding its addressable market from 10 million to 70 million patients, leading to double-digit growth quarter-over-quarter.
- The company expects US guidelines for bempedoic acid to be updated in early 2026 (January/February), anticipated to be similar to the strong Class 1A recommendation received in Europe, which is expected to drive awareness and market penetration.
- Esperion is on track to achieve sustainable profitability in Q1 2026 and begin generating cash flow in 2026, supported by recent debt reduction and up to $120 million in milestones from Japan's approval of bempedoic acid.
- The sales force, currently at 155 representatives, is planned for expansion in 2026 to capitalize on the upcoming US guidelines and the shift in prescription mix towards primary care, which now accounts for 60% of prescriptions.
- The company is actively pursuing business development opportunities for approved or near-approved drugs that can leverage its existing commercial infrastructure, and is advancing a pipeline asset for Primary Sclerosing Cholangitis (PSC) towards Phase I trials within the next 12 months.
Nov 18, 2025, 8:00 AM
Esperion Therapeutics Reports Strong Q3 2025 Results and Strategic Product Developments
ESPR
Revenue Acceleration/Inflection
New Projects/Investments
- Esperion Therapeutics reported Q3 2025 total revenue of $87.3 million, representing nearly 70% year-on-year growth, and Q3 US net product sales of $40.7 million, a 31% year-on-year growth.
- The company finalized agreements with four generic manufacturers, including Dr. Reddy, extending settlements for its products to the year 2040.
- Bempedoic acid received a level 1A recommendation in updated ESC guidelines for the management of dyslipidemia and a class one, level B specifically for statin-intolerant patients.
- Commercial performance for the Nexletol/Nexlizet franchise included a 9% increase quarter-over-quarter in retail prescription equivalents and a 7% increase in total prescribers, now exceeding 30,000 healthcare practitioners.
- Esperion is currently developing a triple combination pill with atorvastatin and rosuvastatin, which modeling suggests could achieve up to 70% LDL reduction.
Nov 11, 2025, 7:00 PM
Esperion Reports Strong Q3 2025 Performance and Strategic Commercial Expansion
ESPR
Earnings
Management Change
Revenue Acceleration/Inflection
- Esperion reported Q3 2025 Total Revenue of $87.3 million, marking a 69% year-over-year growth, and U.S. Net Product Sales of $40.7 million, a 31% year-over-year increase.
- Bempedoic acid received a Level 1a Recommendation in the updated ESC/EAS Guidelines for Management of Dyslipidemia and is the only non-statin FDA approved to lower LDL-C and reduce cardiovascular risk in primary prevention patients.
- The company is expanding its leadership with John Harlow appointed as Chief Commercial Officer, effective November 17, 2025, to lead commercial growth.
- Commercial performance in Q3 2025 included a 9% increase in total retail prescription equivalents and a 7% increase in prescribers quarter-over-quarter, with the total prescriber base now exceeding 30,000 HCPs.
Nov 11, 2025, 7:00 PM
Esperion Reports Strong Q3 2025 Revenue Growth and Clinical Milestone
ESPR
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Esperion reported Q3 2025 total revenue of $87.3 million, representing a 69% year-over-year increase, driven by U.S. net product sales of $40.7 million (up 31% Y/Y) and collaboration revenue of $46.7 million (up 128% Y/Y).
- Bempedoic acid received a Level 1a Recommendation in the updated 2025 ESC/EAS Guidelines for Management of Dyslipidaemias, a significant clinical milestone expected to inform upcoming U.S. guidelines.
- The company ended Q3 2025 with $92.4 million in cash and cash equivalents and reiterated its FY 2025 guidance for R&D expenses of $55 million to $65 million, SG&A expenses of $160 million to $170 million, and total operating expenses of $215 million to $235 million.
- Esperion announced the appointment of John Harlow as Chief Commercial Officer, effective November 17, 2025, to lead future commercial growth.
Nov 6, 2025, 1:00 PM
Esperion Reports Strong Q3 2025 Results, Secures Patent Protection, and Advances International Expansion
ESPR
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Esperion reported strong Q3 2025 financial results, with total revenue growing 69% year over year to $87.3 million. This was driven by a 31% increase in U.S. net product revenue to $40.7 million and an approximately 128% increase in collaboration revenue to $46.7 million.
- The company secured long-term value for its blockbuster franchise by finalizing agreements with four generic manufacturers, including Dr. Reddy's, not to market generic versions of Nexletol and Nexlizet prior to April 2040. Additionally, bempedoic acid products were included as a Class 1, Level A recommendation in the 2025 ESC/EAS guidelines, with similar inclusion anticipated in U.S. guidelines in early 2026.
- Esperion is expanding its international reach, with Otsuka Pharmaceutical receiving favorable preliminary pricing approval in Japan and market approvals expected by year-end 2025 in Canada and Israel. The company remains confident in achieving sustainable profitability in Q1 2026 and reiterated its full-year 2025 operating expense guidance of $215-$235 million.
Nov 6, 2025, 1:00 PM
Esperion Therapeutics Reports Strong Q3 2025 Revenue Growth and Patent Settlement
ESPR
Earnings
Legal Proceedings
Guidance Update
- Esperion Therapeutics reported total revenue of $87.3 million for the third quarter of 2025, marking a 69% increase year-over-year, while also reporting a net loss of $31.3 million for the same period.
- The company reached settlement agreements with four ANDA filers, including Dr. Reddy’s Laboratories, preventing them from marketing generic versions of NEXLETOL and NEXLIZET prior to April 2040.
- Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines, and partner Otsuka received regulatory approval and favorable preliminary pricing for NEXLETOL in Japan, which is expected to trigger significant milestone payments.
- Esperion anticipates achieving sustainable profitability beginning in the first quarter of 2026.
Nov 6, 2025, 12:32 PM
Quarterly earnings call transcripts for Esperion Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more